The cheap-compounded-GLP-1 era is closing. With shortages resolved and enforcement rising, March was a good moment to understand why compounded semaglutide and tirzepatide are not the same as the approved drugs.
Compounded versions of semaglutide and tirzepatide are not FDA-approved, and their legal availability narrowed sharply after the FDA declared the branded-drug shortages resolved and ended related enforcement discretion. March coverage underscored that compounded GLP-1s can carry unknown dosage, purity, and safety profiles compared with approved products.
The window when compounded GLP-1s were broadly available, during the shortage years, has largely closed.
March was a useful moment to revisit what that means for safety and access.
When branded semaglutide and tirzepatide were in shortage, federal rules temporarily allowed compounding pharmacies and outsourcing facilities to prepare versions under specific conditions. With the FDA declaring those shortages resolved, the period of enforcement discretion ended, and compounded copies of these commercially available drugs are generally no longer permitted except in limited, patient-specific circumstances. Litigation over the issue has largely upheld this direction. Compounded drugs, by definition, are not FDA-approved and do not undergo the agency premarket review for safety, effectiveness, and quality.
The safety concern is concrete. Because compounded products are not standardized or FDA-reviewed, they can carry unknown or inconsistent dosage, purity, and quality, and regulators have linked dosing errors to harm. Coverage through early 2026 reiterated that lower cost or easier online access does not equate to equivalent safety, and that products sold without proper oversight, especially online, warrant particular caution.
For consumers, the practical rule sharpened in March: the safest GLP-1 is an FDA-approved product obtained through a licensed prescriber and pharmacy. As compounded access narrows and enforcement rises, relying on unauthorized or online compounded sources carries growing legal and safety risk. With direct-to-consumer pricing of approved products also improving, the historical cost argument for compounded versions is weakening.
Watch for further regulatory steps affecting bulk compounding of GLP-1s and continued enforcement against non-compliant sellers. Pricing of approved products is also evolving, which may further reduce demand for compounded versions. For individuals, the steady guidance is to confirm that any GLP-1 is an FDA-approved product from a lawful, licensed source, and to be skeptical of online sellers offering compounded or unbranded versions at prices that seem too good to be true.